Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Healthcare-associated parechovirus-A infection in hospitals with neonatal units in Japan: a nationwide survey.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026

Same author

BCOR-CCNB3 fusion-positive sarcoma treated with chemotherapy and carbon-ion radiotherapy: a case report of long-term disease control of a cervical spine case with a 12-year follow-up.

Frontiers in oncology·2026

Same author

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity.

Frontiers in oncology·2026

Same author

Prospective use of wastewater surveillance for early detection of enterovirus D68 in community outbreaks among children, Niigata City, Japan, 2024.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026

Same author

Disappearance of histone H3F3A mutation in metastatic giant cell tumor of bone during long term follow up.

Discover oncology·2026

Same author

Successful NIV-NAVA Management for Infant With Respiratory Failure Due to Unilateral Diaphragmatic Paralysis.

Pediatrics international : official journal of the Japan Pediatric Society·2026

Same journal

Wnt activation during epileptogenesis prevents pathological immature dentate granule cell morphological changes in animal models of unilateral and bilateral temporal lobe epilepsy.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Same journal

Protective effects of ACF210, a dual GLP-1/APJ receptor agonist, against cardiovascular-kidney-metabolic syndrome induced by T2D.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Same journal

Tumor microenvironment-mediated interactions between macrophages and cancer cells define immunoregulatory transcriptional programs.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Same journal

Photocontrol of zebrafish behavior with a photoswitchable ligand of nicotinic acetylcholine receptors.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Same journal

Corrigendum to "Ruyiping extract reduces lung metastasis in triple negative breast cancer by regulating macrophage polarization" [Biomed. Pharmacother. 141 (2021) 111883].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Same journal

Microfluidic human liver slices reveal antifibrotic effects of liraglutide via HSC deactivation and ECM remodeling.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

NKG2D-based CAR-T cells for synovial sarcoma: A preclinical proof-of-concept study.

Tomohiro Miyazaki¹, Yudai Murayama², Naoki Oike²

¹Department of Pediatrics, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan; Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie

|June 8, 2026

Summary

This summary is machine-generated.

Chimeric antigen receptor (CAR)-T cell therapy targeting NKG2D ligands shows promise for synovial sarcoma. This HLA-independent approach offers a potential new treatment for patients ineligible for or unresponsive to T cell receptor (TCR)-T therapy.

Keywords:

CAR-T cell therapy Chimeric antigen receptor Immunotherapy Natural killer group 2 member D Synovial sarcoma

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Experiment Videos

Last Updated: Jun 10, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Area of Science:

Oncology
Immunotherapy
Cell Therapy

Background:

Advanced synovial sarcoma has a poor prognosis and limited treatment options.
Current T cell receptor (TCR)-engineered T cell therapy is HLA-restricted, limiting patient eligibility.
Chimeric antigen receptor (CAR)-T cell therapy offers a potential alternative.

Purpose of the Study:

To investigate the potential of NKG2D-ligand targeting CAR-T cells as an HLA-independent therapy for synovial sarcoma.
To evaluate NKG2D-ligand expression in synovial sarcoma.
To assess the in vitro and in vivo efficacy of NKG2D-based CAR-T cells against synovial sarcoma.

Main Methods:

Assessed NKG2D ligand (NKG2DL) surface expression and transcript levels in synovial sarcoma.
Constructed NKG2D-based, 4-1BB-co-stimulated CAR-T cells.
Evaluated CAR-T cell effector functions and anti-tumor effects in vitro and in vivo using a mouse xenograft model.

Main Results:

NKG2DLs were expressed in synovial sarcoma cell lines and tissues.
NKG2D-based CAR-T cells demonstrated effector responses and anti-tumor activity against synovial sarcoma in vitro.
NKG2D-based CAR-T cells exhibited anti-tumor effects in vivo in a synovial sarcoma xenograft model.

Conclusions:

NKG2D-based CAR-T cell therapy is a potential HLA-independent treatment for synovial sarcoma.
This approach may overcome antigen heterogeneity and escape, key challenges in solid tumor CAR-T therapy.
Further validation is needed, but this study provides a preclinical proof of concept for a novel synovial sarcoma therapy.